Amneal Pharmaceuticals

On August 7, 2024, we announced that the U.S. Food and Drug Administration has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease in adults. This video spotlights some of our leaders talking about this exciting milestone. See Important Safety Information at the end of this video and at https://crexont.com/ CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults. Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors. Special thanks (in order of appearance): Chirag Patel, Co-Founder & Co-CEO; Joe Renda, SVP, Chief Commercial Officer Specialty; Chintu Patel, Co-Founder & Co-CEO; Jennifer Altier, VP, Specialty Marketing; Richard D’Souza, SVP, Specialty Pharmaceuticals Research & Development; Candis Edwards, SVP, Regulatory Affairs; Stanley Fisher, VP, Medical Affairs; Hester Visser, VP, Clinical Development; Anita Kumar, VP, R&D; and Lucie Fremeau- Fernandez, Senior Director, Marketing. IMPORTANT SAFETY INFORMATION CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults. Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors. CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery, until you know how CREXONT affects you. The most common side effects that may occur with CREXONT are nausea and anxiety. Do not take CREXONT with alcohol. Tell your healthcare provider if you have any heart conditions; experience hallucinations or abnormal thoughts and behaviors; have abnormal involuntary movements that appear or get worse during treatment; have ever had a peptic ulcer or glaucoma; are or intend to breastfeed; or become or intend to become pregnant. For additional information about CREXONT, please talk with your healthcare provider, or see our website https://crexont.com/. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or https://fda.gov/medwatch

Today, we announced U.S. FDA Approval for Propofol Injectable Emulsion USP, 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL), Single-Dose Vials. Propofol is a commonly used injectable in hospitals for anesthesia and sedation. https://lnkd.in/eW9hYiPP Propofol has a history of shortage due to supply chain constraints. This product is currently on the American Society of Health System Pharmacists (ASHP) drug shortages list. We are working hard to help deliver critical drugs that are in short supply. Propofol is contraindicated in people who have known hypersensitivity to propofol, egg or soybean. See Press Release for additional product information.

Congrats to our U.S. RISE Summer Interns for a successful summer here with us! Last week the team attended a celebration with Co-Founder & Co-CEO Chirag Patel. We are proud of this cohort for all that they have done to make healthy possible.

Bravo to our Brookhaven, New York team! We actively support the health and well-being of the communities where we live, work and serve. And we recognize our commitment to communities includes supporting the well-being of our colleagues around the globe. 

Learn more about how we make healthy possible at Amneal.com

Amneal’s momentum is increasing across our portfolios. We are deeply passionate about our mission and purpose, and the good work that remains ahead. Please reference Amneal’s Second Quarter press release for more information, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: https://lnkd.in/e_EYHtdV

Today, we announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD) in adults. We expect to make CREXONT® available to patients in the U.S. in September and are committed to continuing to advance Parkinson’s research and development as a leader in the space. The most common adverse reactions are nausea and anxiety. For full prescribing information, see our press release and product labeling: https://lnkd.in/eqZWdNi9

We announced U.S. FDA approval for our new presentation of potassium phosphates in 0.9% sodium chloride injection intravenous (IV) ready-to-use (RTU) bags. This sterile presentation reduces the compounding steps for clinicians typically required with administering the product. https://lnkd.in/dz6j_Jvv   Thanks to the expertise and dedication of our global team, we continue to demonstrate our deep capabilities in developing impactful complex products. Adverse effects reported for the potassium phosphates injection IV bags include hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia. For full prescribing information, see package insert: https://lnkd.in/dGE-rWES

Our Cashel, Ireland team continues to advance our inhalation product development portfolio. A dynamic team on a critical mission: to make healthy possible.

We are building on our progress. https://lnkd.in/giE5s3Pb